2019 ASCO Coverage Highlights SPT Week in Review
Top news of the week from Specialty Pharmacy Times.
5. ACA Medicaid Expansion Mitigated Racial Disparity in Timely Cancer Care
Expanded Medicare under the Affordable Care Act nearly eliminated racial disparities in access to timely cancer treatment between African American and white patients.
4. Venetoclax Plus Obinutuzumab Leads to Long-Lasting MRD Negativity in Patients with CLL
Findings presented at the 2019 ASCO meeting show venetoclax plus obinutuzumab induced deep, high, and long-lasting minimal residual disease negativity in chronic lymphocytic leukemia.
3. Novel Drug Therapy Produces Response Rate in Patients with Advanced, Metastatic Urothelial Cancer
The multi-national phase 3 clinical trial on the novel drug as a treatment option for patients with advanced bladder cancer after they’ve received standard chemotherapy and immune treatments.
2. De-Escalation of Bone-Targeted Agents Shows No Change in Efficacy, Safety
Researchers studied the quality of life, pain, Global Health Status, and adverse effects.
1. Oncology Health Care Providers See Benefit of Medical Marijuana, but Not Comfortable Prescribing
A group of health care providers, including 17 pharmacists, indicated in a recent survey that although they believe that medical marijuana likely provides benefits for patients with cancer, less than half were comfortable recommending its use.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
Effectively Managing Immunizations in the Long-Term Care SettingSeptember 18th 2025
Creating a Culture of Quality in Fast-Melt Tablet DevelopmentSeptember 18th 2025
